Antitumor Activity of Axitinib in Lung Carcinoids: A Preclinical Study

被引:2
作者
Dicitore, Alessandra [1 ]
Gaudenzi, Germano [2 ]
Carra, Silvia [3 ]
Cantone, Maria Celeste [2 ]
Oldani, Monica [2 ]
Saronni, Davide [1 ]
Borghi, Maria Orietta [4 ,5 ]
Grotteschi, Jacopo [1 ]
Persani, Luca [1 ,3 ]
Vitale, Giovanni [1 ,2 ]
机构
[1] Univ Milan, Dept Med Biotechnol & Translat Med, I-20122 Milan, Italy
[2] Ist Auxol Italiano, IRCCS, Lab Geriatr & Oncol Neuroendocrinol Res, Milan I-20145, Italy
[3] Ist Auxol Italiano, IRCCS, Lab Endocrine & Metab Res, I-20145 Milan, Italy
[4] Univ Milan, Dept Clin Sci & Community Hlth, I-20122 Milan, Italy
[5] Ist Auxol Italiano, IRCCS, Expt Lab Immuno Rheumatol, I-20145 Milan, Italy
关键词
lung carcinoid; tyrosine kinase inhibitors; axitinib; cell cycle; apoptosis; zebrafish; tumor xenograft; ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; PHASE-II; NEUROENDOCRINE TUMORS; MICROVASCULAR DENSITY; ENDOCRINE TUMORS; OPEN-LABEL; ANGIOGENESIS; EXPRESSION; SUNITINIB;
D O I
10.3390/cancers15225375
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Lung carcinoids (LCs) are categorized as low- and intermediate-grade neuroendocrine tumors. Surgery is effective for localized LCs with a favorable prognosis. However, there is a pressing need for new treatments for unresectable and metastatic LCs. This study explored the potential antitumor effects of axitinib using both in vitro (immortalized cell lines) and in vivo (zebrafish) LC models. Axitinib demonstrated significant antitumor activity by reducing cell viability, inducing cell cycle arrest, and promoting cell death. Moreover, axitinib had a notable impact on crucial processes in tumor progression, including tumor-induced angiogenesis and invasiveness.Abstract Lung carcinoids (LCs) comprise well-differentiated neuroendocrine tumors classified as typical (TCs) and atypical (ACs) carcinoids. Unfortunately, curative therapies remain elusive for metastatic LCs, which account for 25-30% of cases. This study evaluated the antitumor activity of axitinib (AXI), a second-generation tyrosine kinase inhibitor selectively targeting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3) in human lung TC (NCI-H727, UMC-11, NCI-H835) and AC (NCI-H720) cell lines. In vitro and in vivo (zebrafish) assays were performed following AXI treatment to gather several read-outs about cell viability, cell cycle, the secretion of proangiogenic factors, apoptosis, tumor-induced angiogenesis and migration. AXI demonstrated relevant antitumor activity in human LC cells, with pronounced effects observed in UMC-11 and NCI-H720, characterized by cell cycle perturbation and apoptosis induction. AXI significantly hindered tumor induced-angiogenesis in Tg(fli1a:EGFP)y1 zebrafish embryos implanted with all LC cell lines and also reduced the invasiveness of NCI-H720 cells, as well as the secretion of several proangiogenic factors. In conclusion, our study provides initial evidence supporting the potential anti-tumor activity of AXI in LC, offering a promising basis for future investigations in mammalian animal models and, eventually, progressing to clinical trials.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Antitumor Activity of Simvastatin in Preclinical Models of Mantle Cell Lymphoma
    Carvalho Santos, Juliana
    Profitos-Peleja, Nuria
    Lima Ribeiro, Marcelo
    Roue, Gael
    CANCERS, 2022, 14 (22)
  • [22] Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma
    Zakharia, Yousef
    Zakharia, Kais
    Rixe, Olivier
    EXPERT OPINION ON DRUG DISCOVERY, 2015, 10 (08) : 925 - 935
  • [23] Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo
    He, Qiong
    Gao, Jing
    Ge, Sai
    Wang, Tingting
    Li, Yanyan
    Peng, Zhi
    Li, Yilin
    Shen, Lin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (09) : 1575 - 1583
  • [24] Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma
    Lu, Lei
    Saha, Dipongkor
    Martuza, Robert L.
    Rabkin, Samuel D.
    Wakimoto, Hiroaki
    JOURNAL OF NEURO-ONCOLOGY, 2015, 121 (01) : 91 - 100
  • [25] Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer
    Paik, E. Sun
    Kim, Tae-Hyun
    Cho, Young Jae
    Ryu, Jiyoon
    Choi, Jung-Joo
    Lee, Yoo-Young
    Kim, Tae-Joong
    Choi, Chel-Hun
    Kim, Woo Young
    Sa, Jason K.
    Lee, Jin-Ku
    Kim, Byoung-Gie
    Bae, Duk-Soo
    Han, Hee Dong
    Ahn, Hyung Jun
    Lee, Jeong-Won
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [26] The Antitumor Activity of Exogenous and Endogenous Canstatin on Colorectal Cancer Cells
    Xing, Ya-Nan
    Liang, Hong-Wei
    Zhao, Li
    Xu, Hui-Mian
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2011, 12 (10) : 2713 - 2716
  • [27] The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer
    Dredge, K.
    Kink, J. A.
    Johnson, R. M.
    Bytheway, I.
    Marton, L. J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 65 (01) : 191 - 195
  • [28] External Validation of a Prognostic Score for Survival in Lung Carcinoids
    Chiappetta, Marco
    Tabacco, Diomira
    Sassorossi, Carolina
    Sperduti, Isabella
    Cusumano, Giacomo
    Terminella, Alberto
    Fournel, Ludovic
    Alifano, Marco
    Guerrera, Francesco
    Filosso, Pier Luigi
    Nicosia, Samanta
    Gallina, Filippo
    Facciolo, Francesco
    Margaritora, Stefano
    Lococo, Filippo
    CANCERS, 2022, 14 (11)
  • [29] Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study
    Hui, Edwin P.
    Ma, Brigette B. Y.
    Loong, Herbert H. F.
    Mo, Frankie
    Li, Leung
    King, Ann D.
    Wang, Ki
    Ahuja, Anil T.
    Chan, Charles M. L.
    Hui, Connie W. C.
    Wong, Chi H.
    Chan, Anthony T. C.
    CLINICAL CANCER RESEARCH, 2018, 24 (05) : 1030 - 1037
  • [30] Formylated honokiol analogs showed antitumor activity against lung carcinoma
    Deng, Senyi
    Zhang, ChuanFen
    Yang, Lina
    Ma, Liang
    ANTI-CANCER DRUGS, 2019, 30 (08) : 795 - 802